GlassScriptPhysician profile
Robert A Martello
NPI 1205879236
$1,933.57
in general payments reported to CMS, 2019-2025
27 companies · $640 in 2025
The $640 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $460 · 2023: $500 · 2024: $333 · 2025: $640.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,473.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $216.29 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $198.68 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $175.00 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $169.14 | 2022-2025 | Prolia, Evenity, Otezla |
| Pfizer INC. | $138.55 | 2022-2025 | |
| Lilly USA, LLC | $128.29 | 2022-2024 | Mounjaro |
| Glaxosmithkline, LLC. | $124.34 | 2022-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Abbvie INC. | $99.37 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $91.71 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.05 | 2024-2025 | Xifaxan, Trulance |
| Axsome Therapeutics, INC. | $61.37 | 2025 | Auvelity |
| Antares Pharma, INC. | $49.55 | 2022 | |
| Merck Sharp & Dohme LLC | $48.74 | 2024-2025 | Capvaxive |
| Dexcom, INC. | $42.30 | 2023-2024 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $41.73 | 2023 | Spravato |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $40.43 | 2025 | Freestyle Libre 3 |
| Idorsia Pharmaceuticals US INC | $37.20 | 2022 | |
| Radius Health, INC. | $30.60 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.62 | 2023 | Jardiance, Tradjenta |
| Otsuka America Pharmaceutical, INC. | $24.44 | 2024 | Rexulti |
| Eisai INC. | $23.27 | 2025 | |
| Lucid Diagnostics INC. | $19.67 | 2024 | |
| Astellas Pharma US INC | $17.98 | 2022 | |
| Lundbeck LLC | $17.36 | 2023 | Rexulti |
| Sumitomo Pharma America, INC. | $17.35 | 2025 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $15.37 | 2022 | |
| Amneal Pharmaceuticals LLC | $14.17 | 2025 | Unithroid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Martello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.